Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.76 |
| ▸ | ITGAV | P06756 | 20/20 | 0.76 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5972587 | 0.97 | ITGB3 (0.74) | ITGB3ITGAVITGA2B | |
| SCHEMBL5973018 | 0.95 | ITGB3 (0.71) | ITGB3ITGAVITGA2B | |
| SCHEMBL337320 | 0.88 | ITGB3 (0.62) | ITGB3ITGAVITGA2B | |
| SCHEMBL8467709 | 0.87 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL5972809 | 0.85 | ITGB3 (0.81) | ITGB3ITGAVITGA2B | |
| SCHEMBL7078117 | 0.85 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL7074204 | 0.85 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL7072095 | 0.85 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL5972534 | 0.84 | ITGB3 (0.79) | ITGB3ITGAVITGA2B | |
| SCHEMBL8469181 | 0.84 | ITGB3 (0.82) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7090828-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-08-15 | — | — | US | disclosed |
| US-6818201-B2 | FOR ANGIOGENESIS TREATMENT AND DESTRUCTION OF NEW ANGIOGENIC VASCULATURE; USEFUL FOR IMAGING ATHEROSCLEROSIS, RESTENOSIS, CARDIAC ISCHEMIA AND MYOCARDIAL REPERFUSION INJURY; THERAPY OF RHEUMATOID ARTHRITIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-16 | — | — | US | disclosed |
| US-20040014964-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030149262-A1 | Benzodiazepine vitronectin receptor antagonist pharmaceuticals | CHEESMAN EDWARD H (US) | 2003-08-07 | — | — | US | disclosed |
| US-20030143235-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2003-07-31 | — | — | US | disclosed |
| US-6558649-B1 | Benzodiazepine nonpeptide targeting moiety bound to chelating group; diagnosis and treatment of cancer; imaging tumors; monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-6548663-B1 | Imaging tumors and cancer with radioisotope benzodiazepine metal complex as contrast agent | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030143235-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, ADGRE5 | ITGB3 412/4885ITGAV 383/4885ITGA2B 374/4885 |
| US-20030149262-A1 | Benzodiazepine vitronectin receptor antagonist pharmaceuticals | ADGRF1, GPR174, NPSR1 | ITGB3 332/4885ITGAV 223/4885ITGA2B 354/4885 |
| US-20040014964-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | ITGB3 496/4885ITGAV 451/4885ITGA2B 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.